Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-059370
Filing Date
2023-11-06
Accepted
2023-11-06 16:01:01
Documents
68
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cyt-20230930.htm   iXBRL 10-Q 1650765
2 EX-31.1 cyt-ex31_1.htm EX-31.1 18145
3 EX-31.2 cyt-ex31_2.htm EX-31.2 18121
4 EX-32.1 cyt-ex32_1.htm EX-32.1 10264
5 EX-32.2 cyt-ex32_2.htm EX-32.2 10250
  Complete submission text file 0000950170-23-059370.txt   6268712

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20230930.xsd EX-101.SCH 44885
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20230930_pre.xml EX-101.PRE 267366
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cyt-20230930_cal.xml EX-101.CAL 38083
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cyt-20230930_def.xml EX-101.DEF 137792
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20230930_lab.xml EX-101.LAB 363681
62 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20230930_htm.xml XML 1089731
Mailing Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

EIN.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40499 | Film No.: 231379880
SIC: 2834 Pharmaceutical Preparations